Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KANDLELIT-007: Calderasib + SC Pembrolizumab vs SC Pembrolizumab + Chemotherapy in 1L KRAS G12C-Mutant Advanced Nonsquamous NSCLC
NCT07190248Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2025
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 30
01
Overview
Phase 3 trial, sponsored by Merck & Co. Started Oct 2025; status: recruiting.
Beyond the preview
Go deeper on NCT07190248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07190248.